The drug reps for DPP-4 inhibitors, GLP-1 agonists, and various insulins have been having a field day talking to prescribers about the possible cardiovascular effects of SGLT-2 inhibitors. This along with the relatively small risk of UTI’s has possibly caused some of our readers to shy away from the whole class. This week we looked to our SGLT2-I guru, Dr. Stanley Schwartz, to get his thoughts and he provided us with some very useful Homerun Slides to explain how he views the risk for his patients.
Last week our publisher, Steve Freed, had an interview he did on the use of placental biomaterials for wound care. This week, in the second installment, he delves into the question of cost and benefit and how payers are likely to view this treatment in the future.
Our Disaster Averted explains why sometimes the diabetes panacea, weight loss, is not always an indication that a patient is successful, and our Clinical Text looks at the idea that many mononeuropathies, such as carpel tunnel syndrome, may be related to diabetes.